Results 281 to 290 of about 131,040 (312)
Some of the next articles are maybe not open access.

Fluorine-18-fluorodeoxyglucose uptake in pneumonia.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1998
Whole-body PET imaging with 18F-fluorodeoxyglucose (FDG) has been shown to be effective in distinguishing benign and malignant pulmonary disease. Mild elevations in FDG uptake with standardized uptake values (SUVs) less than 2.5 have been reported in benign lesions, including pneumonia.
Luketich, JD   +4 more
openaire   +2 more sources

Panaortitis: Diagnosis via Fluorodeoxyglucose Positron Emission Tomography

The American Journal of the Medical Sciences, 2005
A 57-year-old woman was admitted with a 2-month history of low-grade fever, malaise, and weight loss. Physical examination findings were unremarkable except for a systolic murmur of a known mild aortic regurgitation. Laboratory tests revealed only mild leukocytosis and an elevated sedimentation rate.
Ronen, Zalts   +5 more
openaire   +2 more sources

Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose

Radiologic Clinics of North America, 2004
Twenty-eight years after its inception, 2-[18F]FDG- is still the most widely used radiopharmaceutical for PET studies, but numerous more specific radiotracers have been developed and applied in neuroscience and oncology. The advances in radiotracer chemistry, especially the nucleophilic substitution reaction, have played the pivotal role in ...
Chyng-Yann, Shiue, Michael J, Welch
openaire   +2 more sources

Brain 18F-Fluorodeoxyglucose (FDG) PET

2018
In the last decades, 18F-FDG PET imaging has been extensively used to study glucose brain metabolism [1]. Glucose uptake distribution in the brain is mainly driven by basal neuronal activity and represents general neuronal integrity [2, 3]. The highest values of glucose consumption are found in the basal ganglia, the thalami, and the occipital polar ...
Stefano Fanti   +3 more
openaire   +1 more source

Normal variants in [18F]-fluorodeoxyglucose PET imaging

Radiologic Clinics of North America, 2004
The number of fluorodeoxyglucose PET applications is increasing. In the process of reading fluorodeoxyglucose-PET scans, nuclear medicine physicians encounter a wide variety of normal findings, which must be recognized to determine the best management for patients.
Ghassan, El-Haddad   +4 more
openaire   +2 more sources

Nonmalignant Thoracic Disorders: An Appraisal of Fluorodeoxyglucose and Non-fluorodeoxyglucose PET/Computed Tomography Applications.

PET clinics, 2022
PET/computed tomography (CT) with fluorodeoxyglucose and nonfluorodeoxyglucose PET tracers has established itself in the management of malignant disorders. Its role in the assessment of nonmalignant conditions, such as infectious and noninfectious inflammatory diseases and other benign conditions, has emerged independently and alongside its role being ...
Vandana Kumar, Dhingra   +3 more
openaire   +1 more source

Fluorodeoxyglucose-PET in Breast Cancer

2006
Similar to the previously discussed approved applications in oncology, FDGPET in breast cancer has demonstrated superior diagnostic accuracy compared with conventional anatomic imaging for the detection of distant metastases. This increased accuracy in lesion detection has translated into improved staging, especially in cases with a high clinical ...
Bennett B. Chin   +2 more
openaire   +1 more source

Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity

PET Clinics, 2018
Some malignant lung neoplasms may demonstrate low or absent uptake on F18-fluorodeoxyglucose (FDG) PET/computed tomography. Pathologic type and clinical stage are independent factors associated with FDG avidity. Among lung malignancies with low FDG avidity, adenocarcinoma in situ and carcinoid are the most common.
openaire   +2 more sources

Home - About - Disclaimer - Privacy